Interdependence - the Design System of Politecnico di Milano at the Milan Design Week 2025
Notified -
Globe Newswire10-04-2025, 16:23
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00